Tuvonralimab (QL1706)
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for Tuvonralimab (QL1706), covering 2025-04-23 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer [Phase 2]